Physician profile
Anthony B Joseph
NPI 1669424404
$4,325.08
in general payments reported to CMS, 2019-2025
29 companies · $725 in 2025
The $725 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $478 · 2020: $560 · 2021: $543 · 2022: $528 · 2023: $775 · 2024: $715 · 2025: $725.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,157 · Education: $58.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,156.68 |
| Education | $58.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $619.75 | 2019-2025 | Lokelma, Farxiga |
| Vifor Pharma, INC. | $445.47 | 2019-2025 | Veltassa |
| Akebia Therapeutics INC | $374.24 | 2020-2024 | Auryxia, Vafseo |
| Mallinckrodt Hospital Products INC. | $334.90 | 2020-2025 | Acthar, Terlivaz |
| Otsuka America Pharmaceutical, INC. | $334.87 | 2019-2025 | Jynarque |
| Amgen INC. | $308.75 | 2019-2025 | Tavneos |
| Glaxosmithkline, LLC. | $281.99 | 2019-2024 | Benlysta, Jesduvroq |
| Novartis Pharmaceuticals Corporation | $184.28 | 2020-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $142.72 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $135.09 | 2021-2025 | Jardiance |
| Calliditas Therapeutics US INC. | $128.55 | 2022-2025 | Tarpeyo |
| Horizon Therapeutics Plc | $120.70 | 2020-2023 | Krystexxa |
| Opko Pharmaceuticals, LLC | $116.96 | 2019-2024 | Rayaldee |
| Travere Therapeutics, INC. | $115.31 | 2023-2025 | |
| Fresenius USA Marketing, INC. | $105.48 | 2019-2025 | Velphoro |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $100.25 | 2022-2024 | Lupkynis |
| Daiichi Sankyo INC. | $76.67 | 2020-2023 | Injectafer |
| Lilly USA, LLC | $62.24 | 2023-2025 | Jardiance |
| Mallinckrodt Enterprises LLC | $57.84 | 2019 | |
| Ascendis Pharma Endocrinology INC | $55.37 | 2025 | Yorvipath |
| Alexion Pharmaceuticals, INC. | $35.63 | 2023-2025 | Ultomiris |
| Alnylam Pharmaceuticals INC. | $35.42 | 2023-2024 | Givlaari |
| Apellis Pharmaceuticals, INC. | $34.69 | 2025 | Empaveli |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $28.03 | 2024 | |
| Ardelyx, INC. | $20.81 | 2023 | Ibsrela |
| Novo Nordisk INC | $19.16 | 2024 | |
| Arbor Pharmaceuticals, INC. | $18.11 | 2019 | |
| Nxstage Medical, INC. | $16.00 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $15.80 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Joseph listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.